Document is current

Article History

Received: 11 April 2025

Accepted: 6 February 2026

First Online: 9 March 2026

Declarations

:

: AA is an employee of and owns stock options in Takeda Development Center Americas Inc. CT is an employee of PPD Evidera Patient-Centered Research, part of the PPD clinical research business of Thermo Fisher Scientific, which received funding from Takeda to conduct the work reported in this manuscript. VK is employed by the Section of Hematology and Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA, and was paid by Takeda Development Center Americas Inc. for work related to this study. NK is an employee of PPD Evidera Patient-Centered Research, part of the PPD clinical research business of Thermo Fisher Scientific, which received funding from Takeda to conduct the work reported in this manuscript. NK is a minority shareholder of Thermo Fisher Scientific as part of his employment with PPD Evidera Patient-Centered Research. KM is an employee of PPD Evidera Patient-Centered Research, part of the PPD clinical research business of Thermo Fisher Scientific, which received funding from Takeda to conduct the work reported in this manuscript. KM is a minority shareholder of Thermo Fisher Scientific as part of his employment with PPD Evidera Patient-Centered Research.

: The preference study described in this article was approved by Salus IRB ([formerly Ethical and Independent Review Services]; MO, USA; 19162–01) and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.